Manufacturer of Controlled Substances; Notice of Registration; Pharmacore, Inc., 14299 [2014-05504]
Download as PDF
<![CDATA[
14299
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in
support of product development.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Nektar Therapeutics to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. The DEA has investigated
Nektar Therapeutics to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Schedule
Thebaine (9333) ...........................
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Johnson Matthey, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. The DEA has
investigated, Johnson Matthey, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05489 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2014–05500 Filed 3–12–14; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.
DEPARTMENT OF JUSTICE
By Notice dated November 5, 2013,
and published in the Federal Register
on November 18, 2013, 78 FR 69133,
Johnson Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Manufacturer of Controlled
Substances; Notice of Registration;
Pharmacore, Inc.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
VerDate Mar<15>2010
17:33 Mar 12, 2014
Drug Enforcement Administration
I
II
II
II
II
II
II
II
II
II
II
Jkt 232001
By Notice dated September 27, 2013,
and published in the Federal Register
on October 25, 2013, 78 FR 64017,
PharmaCore, Inc., 4180 Mendenhall
Oaks Parkway, High Point, North
Carolina 27265, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance as active
pharmaceutical ingredients (API) for
clinical trials.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
PharmaCore, Inc., to manufacture the
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
listed basic class of controlled substance
is consistent with the public interest at
this time. The DEA has investigated
PharmaCore, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05504 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2013,
and published in the Federal Register
on October 25, 2013, 78 FR 64017,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
E:\FR\FM\13MRN1.SGM
13MRN1
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Page 14299]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05504]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Pharmacore, Inc.
By Notice dated September 27, 2013, and published in the Federal
Register on October 25, 2013, 78 FR 64017, PharmaCore, Inc., 4180
Mendenhall Oaks Parkway, High Point, North Carolina 27265, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Noroxymorphone (9668), a basic
class of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance as
active pharmaceutical ingredients (API) for clinical trials.
No comments or objections have been received. The DEA has
considered the factors in 21 U.S.C. 823(a) and determined that the
registration of PharmaCore, Inc., to manufacture the listed basic class
of controlled substance is consistent with the public interest at this
time. The DEA has investigated PharmaCore, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic class of controlled substance listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-05504 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P
